Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
VANCOUVER, British Columbia, April 01, 2026 (GLOBE NEWSWIRE) -- Swiss Water Decaffeinated Coffee Inc. (TSX:SWP) (“Swiss Water” or “the Company”), a leading specialty coffee company and premium green...
-
Regina, Sask., March 31, 2026 (GLOBE NEWSWIRE) -- Today, Protein Industries Canada announced a new project in partnership with AGT Foods and Sweet Nutrition aimed at advancing the next generation of...
-
National Canadian Film Day returns on April 15 with more international screenings than ever before
-
Press ReleaseDanish version attached Trifork Digital Health expands into new markets with engagements in Canada and Germany Aarhus, Denmark – March 31, 2026 Trifork Digital Health is expanding its...
-
VANCOUVER, British Columbia, March 31, 2026 (GLOBE NEWSWIRE) -- Li-FT Power Ltd. (“LIFT” or the “Company”) (TSXV: LIFT) (OTCQX: LIFFF) (Frankfurt: WS0) is pleased to announce the launch of the 2026...
-
Marvel Biosciences secures $600,000 in non-dilutive funding from Alberta Innovates to support Phase I clinical trials of its autism-focused patented MB-204
-
Austin, TX, USA, March 27, 2026 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Compostable Flexible Packaging Market Size, Trends and Insights By Material...
-
NACO hosts an embargoed media briefing March 26 on its white paper and recommendations for deploying Budget 2025's $750M early-stage capital allocation.
-
VANCOUVER, British Columbia, March 25, 2026 (GLOBE NEWSWIRE) -- Brixton Metals Corporation (TSX-V: BBB, OTCQX: BBBXF) (the “Company” or “Brixton”) is pleased to announce the third batch of results...
-
Marvel Biosciences Selects Novotech as CRO for Its Phase I Clinical Trial of MB-204, lead asset discovery, a patented neuroactive adenosine A2A antagonist